Immunotherapy: Clinical Trials

44 trials for Immunotherapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

44 unknown. 44 Phase 2, 7 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 244Unknown 44
Phase 17Unknown 7
Phase 31Unknown 1

Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
Vorolanib Tablets, Sintilimab Injection - Renal Cell Carcinoma, Immunotherapy
Phase 2UnknownHao Zeng672024-08-012024-07-26
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
HAIC, Surufatinib, Tislelizumab - Carcinoma, Intrahepatic Cholangiocarcinoma
Phase 2UnknownUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology412023-11-012023-11-18
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Toripalimab - Cervical Cancer, Induction Chemotherapy
Phase 1 / Phase 2UnknownTianjin Medical University Cancer Institute and Hospital202023-11-012025-03-11
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
SBRT, Chemotherapy, PD-1 antibody - Radiotherapy, Immunotherapy
Phase 2UnknownFudan University802023-09-252023-11-07
Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery
Tisleizumab(BGB-A317) - DMMR Colorectal Cancer, Anti PD-1
Phase 2UnknownSun Yat-sen University402023-09-232024-02-16
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
low-dose involved-field radiotherapy combined with immunochemotherapy - Esophageal Squamous Cell Carcinoma (ESCC), Immunotherapy
Phase 2UnknownSichuan University412023-08-242024-12-03
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Envafolimab, CAPEOX - Colon Cancer, Neoadjuvant Therapy
Phase 2UnknownSun Yat-sen University552023-07-012024-04-12
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Disitamab Vedotin combined with fruquintinib and Tislelizumab - HER2-positive Gastric Cancer, Immunotherapy
Phase 1 / Phase 2UnknownFudan University432023-05-092023-08-09
Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers
Terelizumab, CapeOx - Colon Cancer, Immunotherapy
Phase 2Unknownfan li1002023-05-012023-04-27
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Cadonilimab - Immunotherapy, Second-line Treatment
Phase 2UnknownSecond Affiliated Hospital of Zunyi Medical University302023-01-012023-06-18
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Durvalumab, Lenvatinib Oral Product, Chemotherapy - Biliary Tract Neoplasms, Immunotherapy
Phase 2UnknownPeking Union Medical College Hospital402022-12-142023-11-15
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
Paclitaxel-albumin, Cisplatin, Carboplatin - Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes
Phase 2UnknownGuangdong Provincial People's Hospital502022-11-302022-11-28
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Toripalimab, Conventional segmental radiotherapy, opreation - Non-small Cell Lung Cancer, Neoadjuvant Therapy
Phase 2UnknownNorthern Jiangsu People's Hospital202022-08-082023-10-04
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy
Phase 2 / Phase 3UnknownTaizhou Hospital602022-07-012023-04-18
Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric
Envafolimab - Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy
Phase 2UnknownUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology352022-05-302022-05-24
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Tislelizumab, bevacizumab, TAS-102 - Immunotherapy, Colorectal Cancer
Phase 2UnknownFujian Cancer Hospital252022-04-012022-08-23
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
sintilimab, Trastuzumab, S-1 plus oxaliplatin - HER2-positive, Locally Advanced Solid Tumor
Phase 2UnknownAiping Zhou442022-04-012022-04-06
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
Phase 2UnknownLei Li582022-03-272022-04-11
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
Camrelizumab plus Concurrent chemoradiotherapy - Cervical Carcinoma, Chemoradiotherapy
Phase 2UnknownLei Li922022-03-272022-04-13
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W) - Gastric Cancer, Chemotherapy
Phase 2UnknownJiuda Zhao312022-02-152022-04-11

Showing 20 of 44. Sign in to see all of them.

Narrower conditions

Carcinoma, Non-Small-Cell Lung (3)  ·  Colonic Neoplasms (3)  ·  Colorectal Neoplasms (3)  ·  Nasopharyngeal Carcinoma (3)  ·  Uterine Cervical Neoplasms (3)  ·  Biliary Tract Neoplasms (2)  ·  Carcinoma, Renal Cell (2)  ·  Esophageal Squamous Cell Carcinoma (2)  ·  Hypopharyngeal Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Stomach Neoplasms (2)  ·  Brain Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)

Broader conditions

Neoplasms (34)  ·  Neoplasms by Site (33)  ·  Digestive System Diseases (17)  ·  Digestive System Neoplasms (17)  ·  Gastrointestinal Diseases (13)  ·  Gastrointestinal Neoplasms (12)  ·  Neoplasms by Histologic Type (11)  ·  Neoplasms, Glandular and Epithelial (11)  ·  Carcinoma (10)  ·  Head and Neck Neoplasms (10)  ·  Intestinal Diseases (7)  ·  Intestinal Neoplasms (7)  ·  Colonic Diseases (6)  ·  Otorhinolaryngologic Diseases (6)  ·  Pharyngeal Diseases (6)

Interventions

camrelizumab (8)  ·  tislelizumab (7)  ·  sintilimab (6)  ·  toripalimab (5)  ·  Drug Therapy (4)  ·  Radiotherapy (4)  ·  Cisplatin (3)  ·  apatinib (3)  ·  Carboplatin (2)  ·  Immunotherapy (2)  ·  Oxaliplatin (2)  ·  S 1 (combination) (2)  ·  Surgical Procedures, Operative (2)  ·  anlotinib (2)  ·  envafolimab (2)

Sponsors

Sun Yat-sen University (7)  ·  Fudan University (3)  ·  Peking University First Hospital (3)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3)  ·  Lei Li (2)  ·  Shanghai Changzheng Hospital (2)  ·  Tianjin Medical University Cancer Institute and Hospital (2)  ·  West China Hospital (2)  ·  Aiping Zhou (1)  ·  Asan Medical Center (1)  ·  Central Adelaide Local Health Network Incorporated (1)  ·  Eye & ENT Hospital of Fudan University (1)  ·  First Affiliated Hospital of Zhejiang University (1)  ·  Fujian Cancer Hospital (1)  ·  Guangdong Provincial People's Hospital (1)

Countries

China (38)  ·  Australia (1)  ·  South Korea (1)

Top investigators

Lei Li, M.D. (2)  ·  Tao Zhang, MD (2)  ·  Xianshu Gao, MD,PhD (2)  ·  Desheng Hu, Dr. (1)  ·  Fan Xia, M.D,PH.D (1)  ·  Gong Chen, Prof (1)  ·  Guibin Qiao, MD (1)  ·  Hao Zeng (1)  ·  Hao Zeng, Doctor (1)  ·  Hu Ma, Ph.D (1)  ·  Jie Chen (1)  ·  Junlin Yi, MD (1)  ·  Liang Zhou, PhD. (1)  ·  Ming Kuang, Ph.D. (1)  ·  Ming Kuang, PhD (1)

Results publications

PMID 34154614, PMID 34725214, PMID 35476700, PMID 35623069, PMID 36735896, PMID 38637772, PMID 38706247, PMID 38853265, PMID 39144362, PMID 39756446, PMID 40346524, PMID 40810951, PMID 41748259